Skye Bioscience's Involvement in Key Healthcare Conferences
Skye Bioscience, Inc. (NASDAQ: SKYE), a dynamic biopharmaceutical entity, is gearing up for an exciting lineup of healthcare investment conferences. The company focuses on discovering innovative therapeutic pathways aimed at improving metabolic health. This initiative highlights Skye's commitment to advancing their research and engaging with investors and thought leaders in the healthcare community.
Upcoming Conference Schedule
The company will take center stage at several notable conferences, where they will showcase their progress and engage in insightful discussions with potential investors. Their participation includes:
Guggenheim Healthcare Conference
On Monday, November 11, at 1:00 PM ET, Skye will make a presentation at the Guggenheim Healthcare Conference.
UBS Healthcare Conference
Following this, on Wednesday, November 13, at 12:30 PM PT, Skye will participate in a fireside chat at the UBS Healthcare Conference.
Stifel Healthcare Conference
The conference features an important presentation from Skye on Tuesday, November 19, at 3:00 PM ET, where they will discuss their innovative projects.
Craig-Hallum Alpha Select Conference
On the same day, Tuesday, November 19, company representatives will engage in one-on-one meetings at this esteemed conference.
Jefferies Healthcare Conference
Continuing the momentum, Skye will hold meetings from November 19 through 21 at the Jefferies Healthcare Conference in London.
Webcast Access
For those interested in following their presentations and discussions, Skye’s webcasts will be available for streaming on their official website.
About Skye Bioscience
Skye Bioscience is at the forefront of developing next-generation therapeutic solutions that target G-protein coupled receptors. The company prides itself on leveraging biologic targets with meaningful human proof, enabling them to develop first-in-class therapeutics that stand out both clinically and commercially.
Currently, Skye is conducting a Phase 2 clinical trial focused on nimacimab, a unique negative allosteric modulating antibody that inhibits the CB1 receptor peripherally. This trial also assesses the synergetic effects of combining nimacimab with a GLP-1R agonist, showcasing the company’s innovative approach toward addressing obesity and other metabolic conditions.
Contact Information
For additional details about the company’s activities or to inquire about investor relations, Skye encourages direct contact:
Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
Media Inquiries
Michael Fitzhugh
Email: mfitzhugh@lifescicomms.com
Phone: (628) 234-3889
Frequently Asked Questions
What is Skye Bioscience focused on?
Skye Bioscience focuses on developing innovative therapies for metabolic health, particularly through G-protein coupled receptors.
When will Skye present at the Guggenheim Conference?
Skye will present at the Guggenheim Healthcare Conference on November 11 at 1:00 PM ET.
Where will the Jefferies Healthcare Conference take place?
The Jefferies Healthcare Conference will be held in London from November 19 through 21.
What is nimacimab?
Nimacimab is a negative allosteric modulating antibody aimed at treating obesity by inhibiting the CB1 receptor.
How can I access Skye's webcasts?
Webcasts of Skye's presentations can be accessed on their official website.
